Asence is a US-incorporated company that specializes in the supply of quality pharmaceutical preparations (Finished Dosage Forms and Active Pharmaceutical Ingredients) to international markets. Asence has a wholly owned subsidiary company in India - ASENCE PHARMA PVT. LTD. - that manufactures several key Bulk Actives and Finished Dosages. Asence is also associated with the "SARABHAI" group of companies in India and is the exclusive exporter of India 's pharmaceutical conglomerate Ambalal Sarabhai Enterprises Limited (ASE). Asence began its quest in the year 2003 and today has evolved into a specialty pharmaceutical company focused on developing, manufacturing and marketing brand and generic pharmaceutical products utilizing various drug delivery technologies: solid and liquid dosage forms, parenteral, oral controlled release, creams and ointments. Asence through its operations in USA and India markets and distributes pharmaceutical preparations in more than 40 countries worldwide and has more than 100 registered products internationally with an impressive pipeline and capability for development of new medicines. Asence today has the ability to develop, register and supply key upcoming molecules. Asence is also closely associated with manufacturing plants in India and China and sources and supplies key niche products to USA markets as and when it receives an enquiry from clients. Asence ensures that production carried out by its manufacturing partners is in accordance with cGMP guidelines and arranges for regular inspections by Food and Drug Administrations of various countries. We invite you to become familiar with our product range and share in our purpose of enriching human lives.
Ind Swift Laboratories Limited is an Indian company. The Company is engaged in the sale of raw materials to pharmaceutical companies. Its product pipeline consists of 25 products, which include blockbuster drugs, which include Clarithromycin, Atorvastatin and Clopidogrel. It is a wholly owned subsidiary of Ind Swift Laboratories Ltd. (India). It operates in a single segment, which is bulk drugs & Pharmaceuticals. (Source: ARS)
Alembic Limited is a pharmaceutical company. The Company is vertically integrated to develop, manufacture and market pharmaceutical products, pharmaceutical substances and intermediates. Its therapy segments include anti-infective, gynecological, anti-diabetic, anti-hypertensive, cough prep, pain therapy, protein suppliments, anti-ulcerant, nutritional, anti-benign prostatic hyperplasia (BPH). During the fiscal year ended March 31, 2008 (fiscal 2008), it launched 29 products in the market. Zero (sugar free), Glycodin (cough syrup) and Althrocin (Erythromycin) Azithral (Azithromycin), Wikoryl, Roxid are some of the products of the Company. In fiscal 2008, it launched a division called MAXIS, through which it intends to focus on converting generic brands, such as Ciprowin into prescription drug. In January 2008, the Company acquired API manufacturing facility of Nirayu Private Limited.
Morepen Laboratories Limited is an India-based pharmaceutical company. Its principal product is Loratadine. Its other products include Loratadine, Sultamicillin, Atorvastatin Calcium and Montelukast. The Company has presence in segments, such as gastrointestinal, dermatology, respiratory, anti-bacterial and Neuropsychiatry, and has several brands, such as Dom, Acifix, Pentopen, Clarindin, Saltum and Saltumax. During the fiscal year ended March 31, 2007, the Company launched formulations, such as Acloflam, Morser-D, Cefpopen-LB, Cefpen-S, Rabipen, Morepenam and Montelast. It associates with approximately 80,000 doctors and over 100,000 pharmacies for its pharmaceutical products, and has presence in over 200,000 retail outlets for its health products. It also has tie-ups with diagnostics companies, including Beurer, Diamed AG, Hemocue and Menarini for marketing and servicing in India. It has tied up with other pharmaceutical companies for contract manufacturing for them.
J.B. Chemicals & Pharmaceuticals Limited (JBCPL) is an India-based company that operates in the pharmaceuticals industry. The Company manufactures and markets a diverse range of pharmaceutical formulations, herbal remedies and active pharmaceutical ingredient (APIs). JBCPL exports to over 40 countries worldwide with presence in Russia, Ukraine and other Commonwealth of Independent States (CIS) countries. JBCL has a number of manufacturing plants at four locations to manufacture a diverse range of bulk drugs, intermediates, pharmaceutical specialties, radio- diagnostics and herbal remedies. During the year ended March 31, 2008 (fiscal 2008), the Company launched three new products Cilacar, the dual calcium channel blocker; Nicardia XL, which has a osmotic release technology. It also introduced Kvion- natural vitamin K27, which is a treatment for osteoporosis. (Source: ARS)
Sun Pharmaceutical Industries Limited makes specialty pharmaceuticals and active pharmaceutical ingredients (API). Its brands are prescribed in chronic therapy areas, such as cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. Its products introduced during the fiscal year ended March 31, 2007, include Arian, Milmet, Avesta, Sirius, Azura critical care, Solares, Azura life sciences, Sun, Inca, Symbiosis and Synergy. In September 2007, it announced that the United States Food and Drug Administration (FDA) has granted approval for its abbreviated new drug application (ANDA) for Methimazole Tablets USP, five and 10 milligram. In October 2007, the FDA has granted final approval for the Company's ANDA to market its generic version of Novartis Trileptal, oxcarbazepine tablets. In October 2007, it announced that the FDA has granted final marketing approval for its Rivastigmine Tartrate drug.
Aurobindo Pharma was born of a vision. Founded in 1986 by Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed set of professionals, the company became a public venture in 1992. It commenced operations in 1988-89 with a single unit manufacturing semi synthetic penicillins (SSPs) at Pondicherry. Aurobindo Pharma had gone public in 1995 by listing its shares in various stock exchanges in the country. The company is the market leader in semi-synthetic penicillin drugs. It has a presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardio-vascular, gastroenterology, etc. Over the years, the Aurobindo Pharma has evolved into a knowledge driven company. It is R&D focused, has a multi-product portfolio with multi-country manufacturing facilities, and is becoming a marketing conglomerate across the world. Aurobindo Pharma created a name for itself in the manufacture of bulk actives, its area of core competence. After ensuring a firm foundation of cost effective production capabilities and a clutch of loyal customers, the company has entered the high margin speciality generic formulations segment, with a global marketing network. The formulation business is systematically organised with a divisional structure, and has a focused team for each key international market. Aurobindo believes in gaining volume and market share in every business/segment it enters. Aurobindo has invested significant resources in building a mega infrastructure for APIs and formulations to emerge as a vertically integrated pharmaceutical company. Aurobindo's five units for APIs and four units for formulations are designed for the regulated markets. Aurobindo is one of the most reputed sources of Active Pharmaceutical Ingredient in India.
Orchid Chemicals & Pharmaceuticals Ltd. is a pharmaceutical company with research, manufacturing and marketing capabilities. It manufactures active pharmaceutical ingredients and finished dosage forms. Its subsidiary, NCPC Orchid Pharmaceuticals Company Limited, is engaged in the business of manufacture and sale of bulk drugs and formulations; BChD Biotechnological Chemical Development Limited, is engaged in pharmaceutical research and manufacturing; Bexel Pharmaceuticals Inc., is engaged in pharmaceutical research and development; Orchid Pharmaceuticals Inc., markets bulk and formulations, and Gene Arrays Inc., is engaged in pharmaceutical research and development. In June 2007, it received approval from the United States Food and Drug Administration for its abbreviated new drug application for Cefepime injection. In April 2008, it announced the formation of its wholly owned subsidiary Orchid Pharma Japan K K.
Hoechst Marion Roussel AG, a world leader in pharmaceutical-based health care, is dedicated to extending and enhancing human life through the discovery, development, manufacture and sale of pharmaceutical products. The company's major products are among the world's leading therapies for allergic, metabolic and central nervous system disorders as well as cardio-vascular and infectious diseases. In the field of arthritis HMR successfully launched Lefluno-mide (Arava) against rheumatoid arthritis on the US market in 1998. Leflunomide has a novel unique mechanism of action and is the first significant entry of a small molecule Disease Modifying Antirheumatic Drug (DMARD) in more than a decade. Marketing approval in Europe was received in September 1999. Based in Frankfurt, Germany, Hoechst Marion Roussel AG is the pharmaceutical company of Hoechst AG, an international company that focuses on life sciences.
Wockhardt Limited is an India-based pharmaceutical company. The Company is a subsidiary of Khorakwala Holdings and Investments Private Limited. The geographical segments of the Company are India, the United States/Western Europe and Rest of the World. In November 2007, the Company completed the acquisition of Morton Grove Pharmaceuticals Inc. In May 2007, the Company completed the acquisition of Megma Lerads, France. (Source: ARS)
Biocon Limited (Biocon) is engaged in manufacturing biotechnological products in the pharmaceutical through fermentation-based technology, and is also engaged in the formulation business. In the biopharmaceuticals segment, it focuses on the manufacture and marketing of active pharmaceutical ingredients that require fermentation and synthetic chemistry capabilities. Its statins portfolio comprises lovastatin, simvastatin, pravastatin and atorvastatin besides other statins under development. Biocon exports simvastatin to the United States, Europe, Japan and Canada; lovastatin to the United States, and pravastatin to the United States and European markets. Biocon produces mycophenolate mofetil, sirolimus and tacrolimus. It develops and markets a mix of specialty and industrial enzymes for a range of industries, including food, beverages, brewing and distilling, textiles and paper. In October 2007, the Company divested its enzymes business to Novozymes A/S. (Source: ARS)
Established in 1984, Dr. Reddy's Laboratories (NYSE: RDY) is an emerging global pharmaceutical company with proven basic research capabilities. The company develops, manufactures and markets a wide range of pharmaceutical products in India and overseas. Dr. Reddy's produces finished dosage forms, active pharmaceutical ingredients, diagnostic kits, critical care and biotechnology products. The basic research program of Dr. Reddy's focuses on cancer, diabetes, bacterial infections and pain management.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory